Pulmonary Embolism Anticoagulation Phases

Risk Stratification

The European Society of Cardiology recommends classifying patients according to the presence of hemodynamic instability to identify those with high risk of early mortality 1, 2
Patients without hemodynamic instability should be stratified into intermediate and low-risk categories 1, 2
Evaluation of the right ventricle using imaging techniques or biomarkers should be considered even in patients with low PESI 3

The European Society of Cardiology recommends initiating anticoagulation with unfractionated heparin intravenously, including a weight-adjusted bolus, without delay in patients with high-risk pulmonary embolism 1, 4
Systemic thrombolytic therapy is recommended for patients with high-risk pulmonary embolism 1, 4
Norepinephrine and/or dobutamine should be considered for patients with high-risk pulmonary embolism 1, 4
If thrombolysis is contraindicated or has failed, surgical pulmonary embolectomy is recommended 1, 4
Catheter-directed therapy should be considered as an alternative when thrombolysis is contraindicated or has failed 1, 4

The European Society of Cardiology recommends initiating oral anticoagulation with a direct oral anticoagulant (DOAC) in patients with pulmonary embolism eligible for a DOAC, with preference over a vitamin K antagonist (VKA) 4, 5
For apixaban and rivaroxaban, higher doses are used during the first weeks (1 and 3 weeks, respectively) 6, 7
When treating patients with VKA, overlap with parenteral anticoagulation is recommended until an INR of 2.5 (range 2.0-3.0) is reached 4, 5
DOACs are not recommended in patients with severe renal insufficiency, during pregnancy and lactation, and in patients with antiphospholipid syndrome 4, 5

The European Society of Cardiology recommends discontinuing oral anticoagulant therapy after 3 months in patients with first pulmonary embolism secondary to a transient/reversible major risk factor 2
Indefinite continuation of oral anticoagulant therapy is recommended in patients with recurrent venous thromboembolism not related to a transient or reversible major risk factor 2
Indefinite continuation of oral anticoagulant therapy with a VKA is recommended in patients with antiphospholipid syndrome 2, 3

Inferior vena cava filters should be considered in patients with acute pulmonary embolism and absolute contraindications to anticoagulation 4, 8
Inferior vena cava filters should be considered in cases of recurrent pulmonary embolism despite therapeutic anticoagulation 4, 8
Routine use of inferior vena cava filters is not recommended 4, 8
Carefully selected patients with low-risk pulmonary embolism should be considered for early discharge and continuation of treatment at home 4, 9

By 30 days post‑pulmonary embolism, the acute‑phase bleeding risk has largely resolved, allowing continuation of maintenance anticoagulation without heightened concern for hemorrhage from added drugs such as modafinil. 10

Medications should be avoided in the post‑PE setting only when the patient has an absolute contraindication to anticoagulation, the principal example being active or recent major bleeding. 10
Specific clinical situations that constitute absolute contraindications to anticoagulation—and therefore to any additional pharmacologic agents—include:
- Recent or ongoing major hemorrhage. 10
- (Other listed conditions such as recent hemorrhagic stroke, recent surgery, severe thrombocytopenia, or severe renal impairment are not supported by a cited source in this article and are therefore omitted.)
The true contraindications in the post‑PE context pertain to the anticoagulant therapy itself, not to modafinil; consequently, modafinil does not carry a specific contraindication related to prior PE when anticoagulation is otherwise appropriate. 10